World journal of Pharmacy and pharmaceutical sciences最新文献_第5页

Analytical method development and validation for simultaneous estimation of sitagliptin and etruglifloxin in bulk and pharmaceutical dosage form by RP-HPLC 反相高效液相色谱法同时测定西格列汀和依曲格列辛原料药和制剂的分析方法的建立与验证

World journal of Pharmacy and pharmaceutical sciences Pub Date : 2022-01-01 DOI: 10.54037/wjps.2021.91210

C. Parthiban, Aneesa, M. Sudhakar

{"title":"Analytical method development and validation for simultaneous estimation of sitagliptin and etruglifloxin in bulk and pharmaceutical dosage form by RP-HPLC","authors":"C. Parthiban, Aneesa, M. Sudhakar","doi":"10.54037/wjps.2021.91210","DOIUrl":"https://doi.org/10.54037/wjps.2021.91210","url":null,"abstract":"A simple, specific and accurate reverse phase high performance liquid chromatographic method was developed for the simultaneous determination Sitagliptinand Etruglifloxinin pharmaceutical dosage form. The column used was Discovery C18(250mm x 4.6 mm, 5m)in isocratic mode, with mobile phase containing phosphatebufferandacetonitrile (45:55v/v). The buffer is prepared by adding accurately weighed 1.36gm of PotassiumdihyrogenOrtho phosphate in a 1000ml of Volumetric flask add about 900ml of milli-Q water added and degas to sonicate and finally make up the volume with water then pH adjusted to 5.4with dil. Orthophosphoric acid solution.The flow rate was 1.0ml/ min and effluents were monitored at 260nm. The retention times of Sitagliptinand Etruglifloxinwere found to be 2.381min and 3.429min, respectively. The linearity for Sitagliptinand Etruglifloxinwere in the range of 25-150μg/mland 3.75-22.5μg/ml respectively. The recoveries of Sitagliptinand Etruglifloxinwere found to be 99.46to 101.19% and 99.36to 100.99%, respectively. The proposed method was validated and successfully applied to the estimation of Sitagliptinand Etruglifloxinin combined tablet dosage forms.","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80567380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Stability Indicating Method Development and Validation for Simultaneous Estimation of the Netupitant and Palonosetron in Bulk and Pharmaceutical Dosage Form by RP-HPLC 反相高效液相色谱法同时测定尼妥吡坦和帕洛诺司琼原料药和制剂的稳定性指示方法的建立与验证

World journal of Pharmacy and pharmaceutical sciences Pub Date : 2022-01-01 DOI: 10.54037/wjps.2022.100112

Harshini Gandla, M. Ajitha

{"title":"Stability Indicating Method Development and Validation for Simultaneous Estimation of the Netupitant and Palonosetron in Bulk and Pharmaceutical Dosage Form by RP-HPLC","authors":"Harshini Gandla, M. Ajitha","doi":"10.54037/wjps.2022.100112","DOIUrl":"https://doi.org/10.54037/wjps.2022.100112","url":null,"abstract":"A simple, Accurate, precise method was developed for the simultaneous estimation of the Netupitant and Palonosetron in Pharmaceutical dosage form. Chromatogram was run through Phenomenex C18 150 mm (4.6 x 150mm, 5μm) Mobile phase containing Buffer 60% 0.01N KH2PO4: 40% Acetonitrile was pumped through column at a flow rate of 1 ml/min. Temperature was maintained at 30°C. Optimized wavelength selected was 230.0 nm. Retention time of Palonosetron and Netupitant were found to be 2.266 min and 2.945 min. %RSD of the Netupitant and Palonosetron were and found to be 0.8 and 0.8 respectively. %Recovery was obtained as 101.08% and 100.35%for Netupitant and Palonosetron respectively. LOD, LOQ values obtained from regression equations of Netupitant and Palonosetron were 1.27, 3.86 and 0.002, 0.006. respectively. Regression equation of Netupitant is y =18431x + 50471.and y = 13091x + 11.98. of Palonosetron. Retention times were decreased and that run time was decreased, so the method developed was simple and economical that can be adopted in regular Quality control test in Industries.","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91337348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Development and Validation of Stability Indicating Analytical Method for the Simultaneous Estimation of Netarsudil and Latanoprost by RP-HPLC 反相高效液相色谱法同时测定奈沙地尔和拉坦前列素的稳定性指示分析方法的建立与验证

World journal of Pharmacy and pharmaceutical sciences Pub Date : 2022-01-01 DOI: 10.54037/wjps.2022.100111

P. Sharanya, S. Rani

{"title":"Development and Validation of Stability Indicating Analytical Method for the Simultaneous Estimation of Netarsudil and Latanoprost by RP-HPLC","authors":"P. Sharanya, S. Rani","doi":"10.54037/wjps.2022.100111","DOIUrl":"https://doi.org/10.54037/wjps.2022.100111","url":null,"abstract":"A simple, Accurate, Precise method was developed for the simultaneous estimation of the Netarsudil and Latanoprost in opthalmic solution dosage form. Chromatogram was run through Zodiacsil C18 150 x 4.6 mm, 5μ. Mobile phase containing 0.01N Ammonium acetate: Methanol taken with in the ratio 55:45 was pumped through column on a flow rate at 1.0ml/min. Buffer used in this method was Ammonium acetate. Temperature was maintained at 30C. Optimized wavelength selected was 225nm. Retention time of Netarsudil and Latanoprost were found to be 2.222 min and 2.706 min. %RSD of the Netarsudil and Latanoprost were and found to be 0.5 and 0.8 respectively. %Recovery was obtained as 100.09% and 100.5% for Netarsudil and Latanoprost respectively. LOD, LOQ values obtained from regression equations of Netarsudil and Latanoprost were 0.07, 0.22 and 0.03, 0.09 respectively. Regression equation of Netarsudil y = 33253x +578.8 and y =45497x + 399.2 of Latanoprost. Retention times were decreased and that runtime was decreased, so the method developed was simple and economical that can be adopted in regular Quality control test in Industries.","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"111 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73957991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Variation in the efficacy of organic extrants for the phytochemical validation of Sauropus androgynus –a multivitamin plant 多维生素植物——雌雄同体龙的有机萃取剂对其植物化学有效性的影响

World journal of Pharmacy and pharmaceutical sciences Pub Date : 2022-01-01 DOI: 10.54037/wjps.2022.100301

L. S.

引用次数: 0

A BRIEF SYNOPSIS OF MONOCLONAL ANTIBODY FOR THE TREATMENT OF VARIOUS GROUPS OF DISEASES. 单克隆抗体在各类疾病治疗中的应用综述。

World journal of Pharmacy and pharmaceutical sciences Pub Date : 2021-11-01

Aselin Puthenpurail, Hinal Rathi, Surya M Nauli, Ahmmed Ally

{"title":"A BRIEF SYNOPSIS OF MONOCLONAL ANTIBODY FOR THE TREATMENT OF VARIOUS GROUPS OF DISEASES.","authors":"Aselin Puthenpurail, Hinal Rathi, Surya M Nauli, Ahmmed Ally","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Monoclonal antibodies (mAbs) are increasingly being prescribed to patients and investigated in the field of medicine and research. This class of medication is unique due to its ability to be engineered into targeting a specific receptor. Numerous studies and reviews have reported the efficacy, potency, and clinical usage of mAbs in the treatment of a variety of diseases ranging from autoimmune disorders to malignant cancers. However, very few publications classify and provide a brief synopsis of mAbs that includes their pharmacological profiles. mechanisms of action, uses, and side effects in a concise manner. Therefore, this review aims to classify the current mAbs drugs used in clinical practice according to system diseases by providing a brief summary for each of them. For example, regarding cardiovascular disorders, mAbs such as Abciximab, Bevacizumab, and Digoxin Immune Fab will be reviewed. Denosumab, used to treat musculoskeletal disorders, will be also discussed. In addition, mAbs such as Adalimumab, Eculizumab, Natalizumab used in autoimmune disorders and Alemtuzumab, Trastuzumab, Cetuximab, and Rituximab that are prescribed for tumors will be reviewed. Finally, we shall discuss two mAbs that are IL-6 antagonists, Tocilizumab and Siltuximab, which are in ongoing clinical trials as potential treatments of COVID-19. The mAbs have profound benefits against chronic and malignant conditions, and the overall purpose of this review is to illustrate the basic pharmacological profiles of mAbs that physicians may find useful in establishing their management protocols.</p>","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"10 11","pages":"14-22"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775886/pdf/nihms-1770850.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39962856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stability Indicating RP -HPLC Method Development and validation for the simultaneous estimation of Ertugliflozin and Sitagliptin in Bulk and Pharmaceutical Dosage form 稳定性指示反相高效液相色谱法(RP -HPLC):厄图格列净和西格列汀原料药和制剂同时测定方法的建立与验证

World journal of Pharmacy and pharmaceutical sciences Pub Date : 2021-01-01 DOI: 10.54037/wjps.2021.91102

Aleti Rajareddy, A. Divya

引用次数: 2

Formulation and evaluation of transdermal patch of stiripentol for treatment of seizures 施曲妥纳透皮贴剂治疗癫痫发作的研制与评价

World journal of Pharmacy and pharmaceutical sciences Pub Date : 2021-01-01 DOI: 10.54037/wjps.2021.91005

Shubham A. Khadse, M. Mohite

引用次数: 0

Review on solid dispersion for suitable drug 适合药物的固体分散体研究进展

World journal of Pharmacy and pharmaceutical sciences Pub Date : 2021-01-01 DOI: 10.54037/wjps.2021.9911

Sachin Nivrutti Gadekar, Jeevan R. Rajguru, Dr. Subhash V. Deshmane, Dr. K. R. Biyani

引用次数: 0

Formulation and evaluation of Mefenamic acid solid dispersions 甲氧胺酸固体分散体的制备与评价

World journal of Pharmacy and pharmaceutical sciences Pub Date : 2021-01-01 DOI: 10.54037/wjps.2021.9902

Gomathi Murugan, J. Chennakesavalu, Kalaiselvi Chinnamuthu, Soundharya Kaveri

引用次数: 0

Source, isolation & impact of glycone and aglycone in human body glycone和glycone在人体内的来源、分离及影响

World journal of Pharmacy and pharmaceutical sciences Pub Date : 2021-01-01 DOI: 10.54037/wjps.2021.91107

Kushal Nandi, Rimum Ghosh, S. Mondal, D. Sen, D. Saha

引用次数: 1